Business

by Quang T. Nguyen, DO, FACE, FTOS

Evaluating the Benefits and Cost of the Sodium-Glucose Cotransporter 2 Inhibitors

Business, Original Research

Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease

Rashad Carlton, PharmD, MSPH, Rajiv Mallick, PhD, Chelsey Campbell, PharmD, MBA, Aditya Raju, MS, BPharm, Thomas O'Donnell, MD, Michael Eaddy, PharmD, PhD, Michael Eaddy, PharmD, PhD, Michael F. Murphy, MD, PhD

A Teachable Moment in Health Benefits Design

by Michael F. Murphy, MD, PhD

Expect the Unexpected: A Role for Behavioral Economics in Understanding the Impact of Cost- Sharing on Emergency Department Utilization

Albert Tzeel, MD, MHSA, CPE, FAAPL, Jack Brown, BA

by Alberto M. Colombi, MD, MPH

Business, Original Research

Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US Medicaid Population, 2008-2018

Zizi Elsisi, BPharm, Ana L. Hincapie, PhD, Jeff Jianfei Guo, BPharm, PhD

Zizi Elsisi, BPharm; Ana L. Hincapie, PhD; Jeff Jianfei Guo, BPharm, PhD

Utilization Challenges of Drugs for Multiple Sclerosis in a Medicaid Population

James T. Kenney, RPh, MBA

by James T. Kenney, RPh, MBA

Business, Original Research

Online First

Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration

Martin Barnes, MD, George Calcanes, BS, RN, Michael C. Mosier, PhD, Jeffrey Vacirca, MD, FACP, Zulfiqar Malik, MD, PhD

Martin Barnes, MD; George Calcanes, BS, RN; Michael C. Mosier, PhD; Jeffrey Vacirca, MD, FACP; Zulfiqar Malik, MD, PhD

Health Benefit Coverage, Reimbursement, and Influences on Traditional Pharmaceutical Channels

F. Randy Vogenberg, PhD, FASHP

The Many Challenges of Pay-for-Performance Programs

by Gary M. Owens, MD

Health Insurance Premium Increases for the 5 Largest School Districts in the United States, 2004-2008

John R. Cantillo, MBA

by F. Randy Vogenberg, PhD, FASHP

Health Insurance Premium Increases for Large Employers

Health Plan Retention and Pharmacy Costs of Newly Diagnosed Patients with Chronic Kidney Disease in a Managed Care Population

Maureen Kubacki, PharmD, MBA , Chureen Carter, PharmD, MS , Alan D. L. Herrera, PharmD, Jim Wang, PhD, Janice M.S. Lopez, PharmD, MPH, Catherine T. Piech, MBA

Alignment of Incentives along the Healthcare Payer Continuum for Patients with Kidney Disease

by Jeff Januska, PharmD

Health Resource Utilization and Direct Costs Associated with Angina for Patients with Coronary Artery Disease in a US Managed Care Setting

Judy Kempf, PhD, Erin Buysman, MS, Diana Brixner, RPh, PhD, Michael F. Murphy, MD, PhD

Medical Claims Data Can Inform Coverage Decisions in Managed Care Health Plans

Healthcare Costs Among Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea, Shift Work Disorder, or Narcolepsy

Rashad Carlton, PharmD, MSPH, Cathryn A. Carroll, PhD, Orsolya Lunacsek, PhD, Timothy S. Regan, BPharm, RPh, CPh

Out-of-Pocket Cost of Therapy Can Affect Patients’ Excessive Sleepiness and Daytime Functioning

by Teresa DeLuca, MD, MBA